Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Bellerophon Therapeutics, Inc. (BLPH)
Last bellerophon therapeutics, inc. earnings: 4/6 10:23 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.bellerophon.com
Company Research
Source: GlobeNewswire
WARREN, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that the first patient has been randomized into a Phase 2b study evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). The first patient was treated at The Lung Research Center in Chesterfield, MO, by Neil A. Ettinger, M.D. The iNO-PF Phase 2b, randomized, double-blind, placebo-controlled clinical study will assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in patients with PH-ILD, including patients with idiopathic pulmonary fibrosis (PH-IPF). A total of 40 subjects will be enrolled in this clinical trial. The study design includes a 1-week run-in period, followed by an 8-week double-blinded treatment period. The primary endpoint of the study is the change in 6 Minute Walk Distance from baseline to week 8. The trial will include se
Show less
Read more
Impact Snapshot
Event Time:
BLPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLPH alerts
High impacting Bellerophon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BLPH
News
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat